T2 Biosystems

Canaccord Genuity is pleased to announce that on September 19, 2017, it completed a public offering of common stock for T2 Biosystems, Inc. (NASDAQ: TTOO). The Company issued a total of 5,031,250 shares of its common stock at a price to the public of $4.00 per share, which includes the full exercise of the underwriters’ overallotment option. Canaccord Genuity acted as Lead Joint Bookrunning Manager for the offering.

T2 Biosystems, Inc. is an in-vitro diagnostics company that has developed an innovative and proprietary technology platform that offers a rapid, sensitive and simple alternative to existing diagnostic methodologies. The Company utilizes its T2 Magnetic Resonance technology, or T2MR, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. T2’s initial development efforts target sepsis and Lyme disease, which are areas of significant unmet medical need in which existing therapies could be more effective with improved diagnostics.